**Supplementary File 1**

Data from the first assessment (known as pre-baseline) only are reported here, other than if staff and/or resident assessment data were missing and could be replaced with pre-intervention data from one month later (known as the baseline assessment) (*n* = 12). There were no significant differences between first and second assessments on any staff or resident measure (data not shown). This missing data occurred primarily among thirty-eight residents whose antipsychotic prescription was ceased by GPs prematurely, before the planned date. In this situation, medication and facility record data were collected retrospectively to reflect the period before the antipsychotic had ceased, matching the planned HALT schedule. Other assessments were not conducted, with the exception that if possible, retrospective staff or person responsible interviews were completed within 1 month.

|  |
| --- |
| **Supplementary Table 1: Variable correlations with duration of exposure to antipsychotic medications** |
|  | Spearman’s *r* correlation with duration of exposure (*p*) |
| **Sociodemographic characteristics** |  |
| Age  | .44 (.139) |
| Female | .18 (.040) |
| English-speaking COB | .14 (.242) |
|  |  |
| **Care characteristics** |  |
| Duration of residency at LTC facility | .76 (<.001)\* |
| Medical consultations | -.23 (.006)\* |
| Falls | -.13 (.128) |
|  |  |
| **Global functioning** |  |
| Cognition (PAS or RUDAS, lower = more impaired)  | .25 (.018)\* |
| Function (PSMS, higher = more impaired)  | -.26 (.004)\* |
|  |  |
| **Medical history** |  |
| Total number medical diagnoses | -.06 (.483) |
| Depression diagnosis | -.22 (.008)\* |
| Parkinson’s disease diagnosis | .21 (.015)\* |
| Stroke or TIA diagnosis | -.04 (.648) |
|  |  |
| **Medications** |  |
| Dose of regular antipsychotic medication (OLZ equivalent) | .20 (.011)\* |
| Other psychotropics (number) | .04 (.637) |
| Sedatives (number) | -.19 (.027) |
| Analgesics (number) | .03 (.746) |
| Prior recommendation to review current regular antipsychotic (Y/N) | .09 (.317) |
|  |  |
| **Behavioural characteristics** |  |
| Behavioural & psychological symptoms (NPI-NH)  |  |
| Total score | .04 (.704) |
| Occupational disruptiveness total score | -.11 (.218) |
| Psychosis sub-syndrome | -.18 (.060) |
| Hyperactivity sub-syndrome | -.08 (.412) |
| Affective sub-syndrome | .05 (.554) |
| Apathy sub-syndrome | .33 (<.001)\* |
| Agitation/aggression (CMAI)  |  |
| Aggressive behaviour | .01 (.892) |
| Physically nonaggressive behaviour | -.06 (.527) |
| Verbally agitated behaviour | -.14 (.147) |
| Hiding/hoarding | -.01 (.891) |
| Social disengagement (MOSES)  | .24 (.007)\* |
| CMAI = Cohen-Mansfield Agitation Inventory; LTC = long-term care; MOSES = Multidimensional Observation Scale for Elderly Subjects; NPI-NH = Neuropsychiatric Inventory – Nursing Home version; OLZ = olanzapine.\*Statistically significant when adjusted for multiple testing with Holm-Bonferroni method within each set of characteristics (sociodemographic, care, global functioning, medical history, medications, behavioural). |